<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22836511</article-id><article-id pub-id-type="pmc">3419956</article-id><article-id pub-id-type="pii">bjc2012307</article-id><article-id pub-id-type="doi">10.1038/bjc.2012.307</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin <italic>vs</italic> paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients</article-title><alt-title alt-title-type="running">Combination chemotherapy for platinum-sensitive ovarian cancer</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wagner</surname><given-names>U</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Marth</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Largillier</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kaern</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Heywood</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Bonaventura</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Vergote</surname><given-names>I</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Piccirillo</surname><given-names>M C</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Fossati</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Gebski</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Lauraine</surname><given-names>E P</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><aff id="aff1"><label>1</label><institution>Department of Gynecology, Gynecologic Endocrinology and Oncology, University Hospital of Gie&#x000df;en and Marburg, Baldingerstrasse</institution>, 35043 Marburg, <country>Germany</country></aff><aff id="aff2"><label>2</label><institution>Department of Obstetrics &#x00026; Gynecology Medical University Innsbruck</institution>, Innsbruck, <country>Austria</country></aff><aff id="aff3"><label>3</label><institution>Centre Azur&#x000e9;en de Canc&#x000e9;rologie</institution>, Mougins, <country>France</country></aff><aff id="aff4"><label>4</label><institution>Department of Gynecologic Oncology, The Norwegian Radium Hospital</institution>, Oslo, <country>Norway</country></aff><aff id="aff5"><label>5</label><institution>NHMRC Clinical Trials Centre</institution>, Camperdown, New South Wales, <country>Australia</country></aff><aff id="aff6"><label>6</label><institution>Department of Gyn Oncology, Gordon &#x00026; Leslie Diamond Health Centre</institution>, Vancouver, British Columbia, <country>Canada</country></aff><aff id="aff7"><label>7</label><institution>Department of Medical Oncology, Newcastle Mater Misericordia Hospital</institution>, Newcastle, NSW, <country>Australia</country></aff><aff id="aff8"><label>8</label><institution>Department of Obstetrics and Gynaecology, University Hospital Leuven, Leuven Cancer Institute</institution>, Leuven, <country>Belgium</country></aff><aff id="aff9"><label>9</label><institution>Clinical Trials Unit, National Cancer Institute of Napoli</institution>, Napoli, <country>Italy</country></aff><aff id="aff10"><label>10</label><institution>Department of Oncology, Mario Negri Institute</institution>, Milan, <country>Italy</country></aff><aff id="aff11"><label>11</label><institution>Department of Medical Oncology, Universit&#x000e9; Paris Descartes, AP-HP, H&#x000f4;pitaux Universitaires Paris Centre</institution>, Paris, <country>France</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>uwe.wagner@med.uni-marburg.de</email></corresp></author-notes><pub-date pub-type="ppub"><day>07</day><month>08</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>26</day><month>07</month><year>2012</year></pub-date><volume>107</volume><issue>4</issue><fpage>588</fpage><lpage>591</lpage><history><date date-type="received"><day>28</day><month>03</month><year>2012</year></date><date date-type="rev-recd"><day>13</day><month>06</month><year>2012</year></date><date date-type="accepted"><day>18</day><month>06</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2012 Cancer Research UK</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Cancer Research UK</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><license-p>From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/</license-p></license></permissions><abstract><sec><title>Background:</title><p>The CALYPSO phase III trial compared CD (carboplatin-pegylated liposomal doxorubicin (PLD)) with CP (carboplatin-paclitaxel) in patients with platinum-sensitive recurrent ovarian cancer (ROC). Overall survival (OS) data are now mature.</p></sec><sec><title>Methods:</title><p>Women with ROC relapsing &#x0003e;6 months after first- or second-line therapy were randomised to CD or CP for six cycles in this international, open-label, non-inferiority trial. The primary endpoint was progression-free survival. The OS analysis is presented here.</p></sec><sec><title>Results:</title><p>A total of 976 patients were randomised (467 to CD and 509 to CP). With a median follow-up of 49 months, no statistically significant difference was observed between arms in OS (hazard ratio=0.99 (95&#x00025; confidence interval 0.85, 1.16); log-rank <italic>P</italic>=0.94). Median survival times were 30.7 months (CD) and 33.0 months (CP). No statistically significant difference in OS was observed between arms in predetermined subgroups according to age, body mass index, treatment-free interval, measurable disease, number of lines of prior chemotherapy, or performance status. Post-study cross-over was imbalanced between arms, with a greater proportion of patients randomised to CP receiving post-study PLD (68&#x00025;) than patients randomised to CD receiving post-study paclitaxel (43&#x00025; <italic>P</italic>&#x0003c;0.001).</p></sec><sec><title>Conclusion:</title><p>Carboplatin-PLD led to delayed progression and similar OS compared with carboplatin-paclitaxel in platinum-sensitive ROC.</p></sec></abstract><kwd-group><kwd>CALYPSO</kwd><kwd>pegylated liposomal doxorubicin</kwd><kwd>recurrent ovarian cancer</kwd><kwd>overall survival</kwd><kwd>platinum-sensitive</kwd><kwd>carboplatin</kwd><kwd>paclitaxel</kwd></kwd-group></article-meta></front><body><p>In patients with recurrent ovarian cancer (ROC) that is platinum-sensitive (relapsing &#x02a7e;6 months following prior treatment), an analysis of International Collaborative Ovarian Neoplasm (ICON) and Arbeitsgemeinschaft Gyn&#x000e4;kologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) phase III trials demonstrated improved overall survival (OS) with paclitaxel-carboplatin combination chemotherapy compared with carboplatin alone (hazard ratio (HR), 0.82; 95&#x00025; confidence interval (CI), 0.69&#x02013;0.97; <italic>P</italic>=0.02) (<xref ref-type="bibr" rid="bib10">Parmar <italic>et al</italic>, 2003</xref>; <xref ref-type="bibr" rid="bib11">Pfisterer <italic>et al</italic>, 2006</xref>). In a phase II trial of similar design, <xref ref-type="bibr" rid="bib4">Gonz&#x000e1;lez-Mart&#x000ed;n <italic>et al</italic> (2005)</xref> also showed prolonged survival with paclitaxel-carboplatin (HR 0.31; 95&#x00025; CI, 0.14, 0.68; <italic>P</italic>=0.0021). However, this combination is accompanied by a significant toxicity, including peripheral neuropathy, neutropenia, and alopecia. Furthermore, additional survival improvement for this patient population remains an important goal, with a 2-year survival rate of 57&#x00025; observed in the paclitaxel-carboplatin arm of the ICON/AGO-OVAR trials.</p><p>Pegylated liposomal doxorubicin (PLD) has been shown an active drug in platinum-sensitive ROC and has a better toxicity profile than paclitaxel. An earlier study evaluating PLD monotherapy <italic>vs</italic> topotecan demonstrated significantly improved progression-free survival (PFS) and OS in patients receiving PLD (<xref ref-type="bibr" rid="bib5">Gordon <italic>et al</italic>, 2001</xref>, <xref ref-type="bibr" rid="bib6">2004</xref>). The survival benefit was more pronounced for patients with partially sensitive ROC (treatment-free interval (TFI) of &#x0003e;6 months and &#x0003c;12 months). In these patients, the HR for OS was 1.58 compared with 1.15 for those with a TFI&#x0003e;12 months (<xref ref-type="bibr" rid="bib6">Gordon <italic>et al</italic>, 2004</xref>). The Groupe d'Investigateurs Nationaux pour l'&#x000c9;tude des Cancers Ovariens et du sein (GINECO) has explored the combination of PLD and carboplatin in a phase II trial. The OS was 21 months in patients with partially platinum sensitive ROC and 36 months in fully sensitive ROC (<xref ref-type="bibr" rid="bib2">Ferrero <italic>et al</italic>, 2007</xref>). Using the same regimen in a prospective, consecutive cohort, an OS of 30 months was observed in 32 partially sensitive patients and 54 months in 49 fully sensitive patients (<xref ref-type="bibr" rid="bib13">Weber <italic>et al</italic>, 2009</xref>).</p><p>CALYPSO, a large international randomised Gynecologic Cancer Intergroup (GCIG) phase III trial, compared PLD plus carboplatin (CD) to paclitaxel plus carboplatin (CP) in 976 patients with platinum-sensitive ROC (<xref ref-type="bibr" rid="bib12">Pujade-lauraine <italic>et al</italic>, 2010</xref>). The primary endpoint was the non-inferiority of CD relative to CP in PFS. Patients receiving CD experienced a statistically significant improvement in PFS compared with patients receiving CP (HR=0.82 (95&#x00025; CI, 0.72, 0.94); <italic>P</italic>=0.005). Overall severe non-haematologic toxicity (28.4&#x00025; <italic>vs</italic> 36.8&#x00025; <italic>P</italic>=0.001) occurred less frequently in the CD arm, making this regimen an attractive option with a favourable therapeutic index for patients with platinum-sensitive ROC.</p><p>Overall survival data are now mature from CALYPSO. The current analysis investigates whether the observed PFS improvement translated into an OS benefit for patients receiving CD compared with CP for platinum-sensitive ROC.</p><sec sec-type="methods"><title>Patients and methods</title><p>The patients, methods, and design of CALYPSO were previously reported (<xref ref-type="bibr" rid="bib12">Pujade-Lauraine <italic>et al</italic>, 2010</xref>). Briefly, patients had ovarian cancer that recurred &#x0003e;6 months after first- or second-line platinum-based chemotherapy and had received a taxane. Treatment consisted of carboplatin (C) AUC 5 plus PLD 30&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> (CD) on day 1 every 4 weeks or C AUC 5 plus paclitaxel (P) 175&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> (CP) on day 1 every 3 weeks. Patients received six cycles in the absence of disease progression or unacceptable toxicity, with additional cycles allowed for patients experiencing response or stable disease.</p><sec><title>Randomisation and masking</title><p>CALYPSO was an international randomised, phase III, open-label, multicenter trial. Randomisation was performed in permuted blocks with stratification by measurable disease (yes <italic>vs</italic> no), TFI from last chemotherapy (6&#x02013;12 <italic>vs</italic>&#x0003e;12 months), and centre.</p></sec><sec><title>Statistical analysis</title><p>The study design was that of non-inferiority for PFS. The secondary endpoint was OS and analysed using a log-rank test. Exploratory analysis of baseline characteristics was performed with Cox regression and pre-specified subgroups were assessed for differing treatment effects.</p></sec></sec><sec sec-type="results"><title>Results</title><p>A total of 976 patients were randomised between April 2005 and September 2007 (467 to CD and 509 to CP). Baseline patient and disease characteristics were balanced between arms (<xref rid="tbl1" ref-type="table">Table 1</xref>). The majority of patients had FIGO stage III/IV disease and had received only one line of prior treatment. Two-thirds of the patients had a TFI of &#x0003e;12 months since prior chemotherapy. Further details of patient characteristics are reported elsewhere (<xref ref-type="bibr" rid="bib12">Pujade-Lauraine <italic>et al</italic>, 2010</xref>).</p><p>In a prior analysis, PFS was statistically significantly prolonged in the CD arm (HR=0.82 (95&#x00025; CI, 0.72, 0.94); <italic>P</italic>=0.005) based on a median follow-up of 22 months (<xref ref-type="bibr" rid="bib12">Pujade-Lauraine <italic>et al</italic>, 2010</xref>). Median PFS times were 9.4 months in the CP arm and 11.3 months in the CD arm.</p><p>In this analysis, the median follow-up is 49 months (range 0&#x02013;68 months) with a total of 663 deaths: 346 in the CP arm and 317 in the CD arm. The hazard ratio for CP&#x02009;:&#x02009;CD was 0.99 (95&#x00025; CI, 0.85, 1.16), which was not statistically significant (log-rank <italic>P</italic>=0.94; <xref ref-type="fig" rid="fig1">Figure 1</xref>). Median survival times were 30.7 months in the CD arm and 33.0 months in the CP arm.</p><p>Post-study therapy was received by 90&#x00025; of patients in either arm of CALYPSO. The majority of patients (69&#x00025;) received two or more lines (<xref rid="tbl2" ref-type="table">Table 2</xref>). Analysis of cross-over between the arms demonstrated an imbalance. The proportion of patients randomised to CP who received PLD as post-study therapy (68&#x00025;) was higher than the proportion of patients randomised to CD who received paclitaxel as post-study therapy (43&#x00025; <italic>P</italic>&#x0003c;0.001).</p><p>Factors that significantly correlate to survival were age, TFI, ECOG PS, residual disease, CA125, measurable disease, longest lesion size, and disease sites in univariate analyses. In multivariate analysis, TFI&#x02a7e;12 months, ECOG PS 0, CA125&#x0003c;100&#x02009;U&#x02009;ml<sup>&#x02212;1</sup>, non-measurable disease, and one involved disease site remained significantly correlated to survival (<xref rid="tbl3" ref-type="table">Table 3</xref>).</p><p>For <italic>a priori</italic> subgroups age, body mass index, TFI, measurable disease, number of lines of prior chemotherapy, and ECOG performance status, univariate proportional hazards regression for treatment did not show any statistically significant effect (<xref rid="tbl4" ref-type="table">Table 4</xref>).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>CALYPSO is the largest clinical trial in ROC, enroling 976 patients. Designed as a non-inferiority trial, CALYPSO demonstrated that CD was not only non-inferior to CP in PFS but was also superior (HR=0.82, <italic>P</italic>=0.005) in patients with platinum-sensitive ROC. Furthermore, CD was associated with less carboplatin hypersensitivity, peripheral neuropathy, prolonged neutropenia, and alopecia. Toxicities observed more commonly with CD were mucositis, nausea and vomiting, and palmar-plantar erythrodysesthesia. These toxicities were generally low-grade, short-term, and manageable (<xref ref-type="bibr" rid="bib12">Pujade-Lauraine <italic>et al</italic>, 2010</xref>; <xref ref-type="bibr" rid="bib7">Joly <italic>et al</italic>, 2011</xref>). Taken together, CD emerged as a welcome option for treating platinum-sensitive ROC that exhibited a favourable therapeutic index.</p><p>Several analyses of CALYPSO have been undertaken (<xref ref-type="bibr" rid="bib3">Gladieff <italic>et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="bib7">Joly <italic>et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="bib8">Kurtz <italic>et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="bib9">Lee <italic>et al</italic>, 2011</xref>). In the current analysis, OS of CD and CP were evaluated. In the overall population, OS was similar between arms (HR= 0.99; log-rank <italic>P</italic>=0.94). Median survival was 30.7 months in the CD arm. Prior investigations of this regimen have shown median survival times of 25&#x02013;39 months (<xref ref-type="bibr" rid="bib2">Ferrero <italic>et al</italic>, 2007</xref>; <xref ref-type="bibr" rid="bib13">Weber <italic>et al</italic>, 2009</xref>; <xref ref-type="bibr" rid="bib1">Bafaloukos <italic>et al</italic>, 2010</xref>). Median survival in the CP arm was 33.0 months; historical data have shown 29 months (<xref ref-type="bibr" rid="bib10">Parmar <italic>et al</italic>, 2003</xref>; <xref ref-type="bibr" rid="bib1">Bafaloukos <italic>et al</italic>, 2010</xref>).</p><p>When analysed by patient subgroups according to age, BMI, TFI, measurable disease, number of prior therapy lines, and ECOG PS, no statistically significant differences emerged between treatment arms in any of the subgroups. Notable was the lack of difference between arms regardless of TFI. The HR for OS in the partially platinum-sensitive subgroup (TFI 6&#x02013;12 months) was 1.01 (95&#x00025; CI, 0.80, 1.28; <italic>P</italic>=0.92), whereas the HR for OS in the sensitive subgroup (TFI&#x0003e;12 months) was 0.99 (95&#x00025; CI, 0.81, 1.21; <italic>P</italic>=0.90). These results lie in contrast to the study of monotherapy PLD <italic>vs</italic> topotecan, which showed a more pronounced survival benefit for PLD relative to topotecan in patients with partially platinum-sensitive disease (<xref ref-type="bibr" rid="bib6">Gordon <italic>et al</italic>, 2004</xref>).</p><p>An imbalance in post-study therapy may have affected OS and mitigated the PFS benefit observed with CD. Post-study PLD was received by 68&#x00025; of patients in the CP arm, while post-study paclitaxel was administered to 43&#x00025; of patients in the CD arm (<italic>P</italic>&#x0003c;0.001).</p><p>The results of CALYPSO demonstrate that carboplatin-PLD offers an attractive option as compared with the standard of care, carboplatin-paclitaxel, for the treatment of platinum-sensitive ROC. Patients receiving carboplatin-PLD experienced delayed progression, similar survival, less carboplatin hypersensitivity, and less peripheral neuropathy, a toxicity associated with long-term sequelae, compared with patients receiving carboplatin-paclitaxel.</p></sec></body><back><ack><p>We acknowledge the women who participated in this study as well as the investigators and their staff, Phillips Gilmore and Laura Evans for editing and technical assistance in preparation of the manuscript. Research support provided by Merck, formerly Schering-Plough Corporation.</p><p><bold>Participant Institutions</bold></p><p>AGO; AGO-Austria; GINECO; NSGO; Stat; NCI-CTG; ANZGOG; EORTC; MITO; MANGO; Stat; GINECO</p></ack><fn-group><fn><p>This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.</p></fn><fn><p>This study was previously presented at the 2011 American Society of Clinical Oncology Annual Meeting: Marth C, Alexandre J, Hanker LC, <italic>et al.</italic> Pegylated liposomal doxorubicin and carboplatin (C-PLD) <italic>versus</italic> paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial. <italic>J Clin Oncol</italic>
<bold>29</bold>: 2011 (suppl; abstr 5052).</p></fn></fn-group><notes><p>The authors declare no conflict of interest.</p></notes><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bafaloukos</surname><given-names>D</given-names></name><name><surname>Linardou</surname><given-names>H</given-names></name><name><surname>Aravantinos</surname><given-names>G</given-names></name><name><surname>Papadimitriou</surname><given-names>C</given-names></name><name><surname>Bamias</surname><given-names>A</given-names></name><name><surname>Fountzilas</surname><given-names>G</given-names></name><name><surname>Kalofonos</surname><given-names>HP</given-names></name><name><surname>Kosmidis</surname><given-names>PE</given-names></name><name><surname>Makatsoris</surname><given-names>T</given-names></name><name><surname>Samantas</surname><given-names>E</given-names></name><name><surname>Briasoulis</surname><given-names>E</given-names></name><name><surname>Christodoulou</surname><given-names>C</given-names></name><name><surname>Papakostas</surname><given-names>P</given-names></name><name><surname>Pectasides</surname><given-names>D</given-names></name><name><surname>Dimopoulos</surname><given-names>AM</given-names></name></person-group><year>2010</year><article-title>A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study</article-title><source>BMC Med</source><volume>8</volume><fpage>3</fpage><pub-id pub-id-type="pmid">20055981</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrero</surname><given-names>JM</given-names></name><name><surname>Weber</surname><given-names>B</given-names></name><name><surname>Geay</surname><given-names>JF</given-names></name><name><surname>Lepille</surname><given-names>D</given-names></name><name><surname>Orfeuvre</surname><given-names>H</given-names></name><name><surname>Combe</surname><given-names>M</given-names></name><name><surname>Mayer</surname><given-names>F</given-names></name><name><surname>Leduc</surname><given-names>B</given-names></name><name><surname>Bourgeois</surname><given-names>H</given-names></name><name><surname>Paraiso</surname><given-names>D</given-names></name><name><surname>Pujade-Lauraine</surname><given-names>E</given-names></name></person-group><year>2007</year><article-title>Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial</article-title><source>Ann Oncol</source><volume>18</volume><fpage>263</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">17108151</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gladieff</surname><given-names>L</given-names></name><name><surname>Ferrero</surname><given-names>A</given-names></name><name><surname>De Rauglaudre</surname><given-names>G</given-names></name><name><surname>Brown</surname><given-names>C</given-names></name><name><surname>Vasey</surname><given-names>P</given-names></name><name><surname>Reinthaller</surname><given-names>A</given-names></name><name><surname>Pujade-Lauraine</surname><given-names>E</given-names></name><name><surname>Reed</surname><given-names>N</given-names></name><name><surname>Lorusso</surname><given-names>D</given-names></name><name><surname>Siena</surname><given-names>S</given-names></name><name><surname>Helland</surname><given-names>H</given-names></name><name><surname>Elit</surname><given-names>L</given-names></name><name><surname>Mahner</surname><given-names>S</given-names></name></person-group><year>2011</year><article-title>Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial</article-title><source>Ann Oncol</source><volume>23</volume><fpage>1185</fpage><lpage>1189</lpage><pub-id pub-id-type="pmid">21976386</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x000e1;lez-Mart&#x000ed;n</surname><given-names>AJ</given-names></name><name><surname>Calvo</surname><given-names>E</given-names></name><name><surname>Bover</surname><given-names>I</given-names></name><name><surname>Rubio</surname><given-names>MJ</given-names></name><name><surname>Arcusa</surname><given-names>A</given-names></name><name><surname>Casado</surname><given-names>A</given-names></name><name><surname>Ojeda</surname><given-names>B</given-names></name><name><surname>Bala&#x000f1;&#x000e1;</surname><given-names>C</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>E</given-names></name><name><surname>Herrero</surname><given-names>A</given-names></name><name><surname>Pardo</surname><given-names>B</given-names></name><name><surname>Adrover</surname><given-names>E</given-names></name><name><surname>Rif&#x000e1;</surname><given-names>J</given-names></name><name><surname>Godes</surname><given-names>MJ</given-names></name><name><surname>Moyano</surname><given-names>A</given-names></name><name><surname>Cervantes</surname><given-names>A</given-names></name></person-group><year>2005</year><article-title>Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espa&#x000f1;ol de Investigaci&#x000f3;n en C&#x000e1;ncer de Ovario) study</article-title><source>Ann Oncol</source><volume>16</volume><fpage>749</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">15817604</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>A</given-names></name><name><surname>Fleagle</surname><given-names>J</given-names></name><name><surname>Guthrie</surname><given-names>D</given-names></name><name><surname>Parkin</surname><given-names>D</given-names></name><name><surname>Gore</surname><given-names>M</given-names></name><name><surname>Lacave</surname><given-names>A</given-names></name></person-group><year>2001</year><article-title>Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan</article-title><source>J Clin Oncol</source><volume>19</volume><fpage>3312</fpage><lpage>3322</lpage><pub-id pub-id-type="pmid">11454878</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>A</given-names></name><name><surname>Tonda</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Rackoff</surname><given-names>W</given-names></name><collab>Doxil Study 30&#x02013;49 Investigators</collab></person-group><year>2004</year><article-title>Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer</article-title><source>Gynecol Oncol</source><volume>95</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15385103</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joly</surname><given-names>F</given-names></name><name><surname>Ray-Coquard</surname><given-names>I</given-names></name><name><surname>Fabbro</surname><given-names>M</given-names></name><name><surname>Donoghoe</surname><given-names>M</given-names></name><name><surname>Boman</surname><given-names>K</given-names></name><name><surname>Sugimoto</surname><given-names>A</given-names></name><name><surname>Vaughan</surname><given-names>M</given-names></name><name><surname>Reinthaller</surname><given-names>A</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name><name><surname>Ferrandina</surname><given-names>G</given-names></name><name><surname>Dell'Anna</surname><given-names>T</given-names></name><name><surname>Huober</surname><given-names>J</given-names></name><name><surname>Pujade-Lauraine</surname><given-names>E</given-names></name></person-group><year>2011</year><article-title>Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial</article-title><source>Gynecol Oncol</source><volume>122</volume><fpage>226</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">21575983</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurtz</surname><given-names>JE</given-names></name><name><surname>Kaminsky</surname><given-names>MC</given-names></name><name><surname>Floquet</surname><given-names>A</given-names></name><name><surname>Veillard</surname><given-names>AS</given-names></name><name><surname>Kimmig</surname><given-names>R</given-names></name><name><surname>Dorum</surname><given-names>A</given-names></name><name><surname>Elit</surname><given-names>L</given-names></name><name><surname>Buck</surname><given-names>M</given-names></name><name><surname>Petru</surname><given-names>E</given-names></name><name><surname>Reed</surname><given-names>N</given-names></name><name><surname>Scambia</surname><given-names>G</given-names></name><name><surname>Varsellona</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>C</given-names></name><name><surname>Pujade-Lauraine</surname><given-names>E</given-names></name><collab>Gynecologic Cancer Intergroup</collab></person-group><year>2011</year><article-title>Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study</article-title><source>Ann Oncol</source><volume>22</volume><fpage>2417</fpage><lpage>2423</lpage><pub-id pub-id-type="pmid">21402619</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CK</given-names></name><name><surname>Friedlander</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>C</given-names></name><name><surname>Gebski</surname><given-names>VJ</given-names></name><name><surname>Georgoulopoulos</surname><given-names>A</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name><name><surname>Pignata</surname><given-names>S</given-names></name><name><surname>Donadello</surname><given-names>N</given-names></name><name><surname>Schmalfeldt</surname><given-names>B</given-names></name><name><surname>Delva</surname><given-names>R</given-names></name><name><surname>Mirza</surname><given-names>MR</given-names></name><name><surname>Sauthier</surname><given-names>P</given-names></name><name><surname>Pujade-Lauraine</surname><given-names>E</given-names></name><name><surname>Lord</surname><given-names>SJ</given-names></name><name><surname>Simes</surname><given-names>RJ</given-names></name></person-group><year>2011</year><article-title>Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer</article-title><source>J Natl Cancer Inst</source><volume>103</volume><fpage>1338</fpage><lpage>1342</lpage><pub-id pub-id-type="pmid">21840849</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parmar</surname><given-names>MK</given-names></name><name><surname>Ledermann</surname><given-names>JA</given-names></name><name><surname>Colombo</surname><given-names>N</given-names></name><name><surname>du Bois</surname><given-names>A</given-names></name><name><surname>Delaloye</surname><given-names>JF</given-names></name><name><surname>Kristensen</surname><given-names>GB</given-names></name><name><surname>Wheeler</surname><given-names>S</given-names></name><name><surname>Swart</surname><given-names>AM</given-names></name><name><surname>Qian</surname><given-names>W</given-names></name><name><surname>Torri</surname><given-names>V</given-names></name><name><surname>Floriani</surname><given-names>I</given-names></name><name><surname>Jayson</surname><given-names>G</given-names></name><name><surname>Lamont</surname><given-names>A</given-names></name><name><surname>Trop&#x000e9;</surname><given-names>C</given-names></name><collab>ICON and AGO Collaborators</collab></person-group><year>2003</year><article-title>Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial</article-title><source>Lancet</source><volume>361</volume><fpage>2099</fpage><lpage>2106</lpage><pub-id pub-id-type="pmid">12826431</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfisterer</surname><given-names>J</given-names></name><name><surname>Plante</surname><given-names>M</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name><name><surname>du Bois</surname><given-names>A</given-names></name><name><surname>Hirte</surname><given-names>H</given-names></name><name><surname>Lacave</surname><given-names>AJ</given-names></name><name><surname>Wagner</surname><given-names>U</given-names></name><name><surname>St&#x000e4;hle</surname><given-names>A</given-names></name><name><surname>Stuart</surname><given-names>G</given-names></name><name><surname>Kimmig</surname><given-names>R</given-names></name><name><surname>Olbricht</surname><given-names>S</given-names></name><name><surname>Le</surname><given-names>T</given-names></name><name><surname>Emerich</surname><given-names>J</given-names></name><name><surname>Kuhn</surname><given-names>W</given-names></name><name><surname>Bentley</surname><given-names>J</given-names></name><name><surname>Jackisch</surname><given-names>C</given-names></name><name><surname>L&#x000fc;ck</surname><given-names>HJ</given-names></name><name><surname>Rochon</surname><given-names>J</given-names></name><name><surname>Zimmermann</surname><given-names>AH</given-names></name><name><surname>Eisenhauer</surname><given-names>E</given-names></name><collab>AGO-OVAR, NCIC CTG, EORTC GCG</collab></person-group><year>2006</year><article-title>Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG</article-title><source>J Clin Oncol</source><volume>24</volume><fpage>4699</fpage><lpage>4707</lpage><pub-id pub-id-type="pmid">16966687</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pujade-Lauraine</surname><given-names>E</given-names></name><name><surname>Wagner</surname><given-names>U</given-names></name><name><surname>Aavall-Lundqvist</surname><given-names>E</given-names></name><name><surname>Gebski</surname><given-names>V</given-names></name><name><surname>Heywood</surname><given-names>M</given-names></name><name><surname>Vasey</surname><given-names>PA</given-names></name><name><surname>Volgger</surname><given-names>B</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name><name><surname>Pignata</surname><given-names>S</given-names></name><name><surname>Ferrero</surname><given-names>A</given-names></name><name><surname>Sehouli</surname><given-names>J</given-names></name><name><surname>Lortholary</surname><given-names>A</given-names></name><name><surname>Kristensen</surname><given-names>G</given-names></name><name><surname>Jackisch</surname><given-names>C</given-names></name><name><surname>Joly</surname><given-names>F</given-names></name><name><surname>Brown</surname><given-names>C</given-names></name><name><surname>Le Fur</surname><given-names>N</given-names></name><name><surname>du Bois</surname><given-names>A</given-names></name></person-group><year>2010</year><article-title>Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse</article-title><source>J Clin Oncol</source><volume>28</volume><fpage>3323</fpage><lpage>3329</lpage><pub-id pub-id-type="pmid">20498395</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>B</given-names></name><name><surname>Lortholary</surname><given-names>A</given-names></name><name><surname>Mayer</surname><given-names>F</given-names></name><name><surname>Bourgeois</surname><given-names>H</given-names></name><name><surname>Orfeuvre</surname><given-names>H</given-names></name><name><surname>Combe</surname><given-names>M</given-names></name><name><surname>Platini</surname><given-names>C</given-names></name><name><surname>Cretin</surname><given-names>J</given-names></name><name><surname>Fric</surname><given-names>D</given-names></name><name><surname>Paraiso</surname><given-names>D</given-names></name><name><surname>Pujade-Lauraine</surname><given-names>E</given-names></name></person-group><year>2009</year><article-title>Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial</article-title><source>Anticancer Res</source><volume>29</volume><fpage>4195</fpage><lpage>4200</lpage><pub-id pub-id-type="pmid">19846972</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p>Overall survival in patients receiving carboplatin-paclitaxel or carboplatin-PLD for platinum-sensitive recurrent ovarian cancer. Abbreviation: PLD, pegylated liposomal doxorubicin.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2012307f1"/></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Baseline characteristics</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="char" char=""/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50"><bold>CD <italic>n</italic>=466</bold></th><th align="center" valign="top" charoff="50"><bold>CP <italic>n</italic>=509</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td colspan="2" align="center" valign="top" charoff="50"><italic>n</italic> (&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">Median age, years</td><td align="center" valign="top" charoff="50">60.5</td><td align="center" valign="top" charoff="50">61.0</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>ECOG performance status</italic><xref ref-type="fn" rid="t1-fn2">a</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;0</td><td align="char" valign="top" char="(" charoff="50">286 (61)</td><td align="char" valign="top" char="(" charoff="50">317 (62)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="char" valign="top" char="(" charoff="50">159 (34)</td><td align="char" valign="top" char="(" charoff="50">164 (32)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="char" valign="top" char="(" charoff="50">13 (3)</td><td align="char" valign="top" char="(" charoff="50">15 (3)</td></tr><tr><td align="left" valign="top" charoff="50">Primary disease site ovarian</td><td align="char" valign="top" char="(" charoff="50">415 (89)</td><td align="char" valign="top" char="(" charoff="50">451 (89)</td></tr><tr><td align="left" valign="top" charoff="50">Papillary/serous histology</td><td align="char" valign="top" char="(" charoff="50">334 (72)</td><td align="char" valign="top" char="(" charoff="50">366 (72)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Initial FIGO stage</italic><xref ref-type="fn" rid="t1-fn2">a</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;I/II</td><td align="char" valign="top" char="(" charoff="50">52 (11)</td><td align="char" valign="top" char="(" charoff="50">59 (12)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;III/IV</td><td align="char" valign="top" char="(" charoff="50">401 (86)</td><td align="char" valign="top" char="(" charoff="50">427 (84)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Number of previous therapy lines</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="char" valign="top" char="(" charoff="50">408 (88)</td><td align="char" valign="top" char="(" charoff="50">421 (83)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="char" valign="top" char="(" charoff="50">58 (12)</td><td align="char" valign="top" char="(" charoff="50">87 (17)</td></tr><tr><td align="left" valign="top" charoff="50">Prior taxane</td><td align="char" valign="top" char="(" charoff="50">462 (99)</td><td align="char" valign="top" char="(" charoff="50">500 (99)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Median interval since prior therapy</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;6&#x02013;12 months</td><td align="char" valign="top" char="(" charoff="50">162 (35)</td><td align="char" valign="top" char="(" charoff="50">182 (36)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;12 months</td><td align="char" valign="top" char="(" charoff="50">304 (65)</td><td align="char" valign="top" char="(" charoff="50">326 (64)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Measurable disease</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Yes</td><td align="char" valign="top" char="(" charoff="50">281 (60)</td><td align="char" valign="top" char="(" charoff="50">321 (63)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;No</td><td align="char" valign="top" char="(" charoff="50">185 (39)</td><td align="char" valign="top" char="(" charoff="50">188 (37)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Tumour size</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003c;5&#x02009;cm</td><td align="char" valign="top" char="(" charoff="50">377 (81)</td><td align="char" valign="top" char="(" charoff="50">419 (82)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02a7e;5&#x02009;cm</td><td align="char" valign="top" char="(" charoff="50">89 (19)</td><td align="char" valign="top" char="(" charoff="50">90 (18)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50"><italic>Number of sites of recurrence</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="char" valign="top" char="(" charoff="50">217 (47)</td><td align="char" valign="top" char="(" charoff="50">245 (48)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;1</td><td align="char" valign="top" char="(" charoff="50">249 (53)</td><td align="char" valign="top" char="(" charoff="50">264 (52)</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviations: CD=carboplatin-pegylated liposomal doxorubicin; CP=carboplatin-paclitaxel; ECOG=Eastern Cooperative Oncology Group.</p></fn><fn id="t1-fn2"><label>a</label><p>Missing values to attain 100&#x00025;.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2"><label>Table 2</label><caption><title>Number of post-study therapy lines and cross-overs</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Treatment</bold></th><th align="center" valign="top" char="." charoff="50"><bold>Patients (&#x00025;)</bold></th></tr></thead><tbody valign="top"><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Number of lines</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;0</td><td align="char" valign="top" char="." charoff="50">10</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="char" valign="top" char="." charoff="50">21</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="char" valign="top" char="." charoff="50">25</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;3</td><td align="char" valign="top" char="." charoff="50">21</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;4</td><td align="char" valign="top" char="." charoff="50">13</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;5&#x02013;11</td><td align="char" valign="top" char="." charoff="50">10</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2 or more lines</td><td align="char" valign="top" char="." charoff="50">69</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Cross-overs</italic><xref ref-type="fn" rid="t2-fn2">a</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;CP arm</td><td align="char" valign="top" char="." charoff="50">68</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;CD arm</td><td align="char" valign="top" char="." charoff="50">43</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>Abbreviations: CD=carboplatin-pegylated liposomal doxorubicin; CP=carboplatin-paclitaxel.</p></fn><fn id="t2-fn2"><label>a</label><p><italic>P</italic>&#x0003c;0.001 for comparison between arms.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3"><label>Table 3</label><caption><title>Multivariate cox regression model of overall survival (<italic>N</italic>=959)</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Factors</bold></th><th align="center" valign="top" charoff="50"><italic><bold>N</bold></italic></th><th align="center" valign="top" charoff="50"><bold>HR</bold></th><th align="center" valign="top" charoff="50"><bold>95&#x00025; CI</bold></th><th align="center" valign="top" charoff="50"><italic><bold>P</bold></italic><bold>-value</bold></th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>TFI, months</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;6&#x02013;12</td><td align="char" valign="top" char="." charoff="50">342</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02a7e;12</td><td align="char" valign="top" char="." charoff="50">617</td><td align="char" valign="top" char="." charoff="50">0.50</td><td align="char" valign="top" char="." charoff="50">0.43, 0.59</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>ECOG PS</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;0<xref ref-type="fn" rid="t3-fn2">a</xref></td><td align="char" valign="top" char="." charoff="50">615</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02a7e;1</td><td align="char" valign="top" char="." charoff="50">344</td><td align="char" valign="top" char="." charoff="50">1.37</td><td align="char" valign="top" char="." charoff="50">1.17, 1.60</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>CA125, U&#x02009;ml</italic><sup>&#x02212;<italic>1</italic></sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003c;100</td><td align="char" valign="top" char="." charoff="50">316</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02a7e;100</td><td align="char" valign="top" char="." charoff="50">643</td><td align="char" valign="top" char="." charoff="50">1.78</td><td align="char" valign="top" char="." charoff="50">1.49, 2.14</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Measurable disease/longest lesion, mm</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;No</td><td align="char" valign="top" char="." charoff="50">361</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02a7d;50</td><td align="char" valign="top" char="." charoff="50">422</td><td align="char" valign="top" char="." charoff="50">1.28</td><td align="char" valign="top" char="." charoff="50">1.04, 1.57</td><td align="char" valign="top" char="." charoff="50">0.02</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;50</td><td align="char" valign="top" char="." charoff="50">176</td><td align="char" valign="top" char="." charoff="50">1.78</td><td align="char" valign="top" char="." charoff="50">1.40, 2.26</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Involved disease sites</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="char" valign="top" char="." charoff="50">453</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;1</td><td align="char" valign="top" char="." charoff="50">506</td><td align="char" valign="top" char="." charoff="50">1.26</td><td align="char" valign="top" char="." charoff="50">1.05, 1.52</td><td align="char" valign="top" char="." charoff="50">0.014</td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><p>Abbreviations: CI=confidence interval; ECOG PS=Eastern Cooperative Oncology Group performance status; HR=hazard ratio; TFI=treatment-free interval.</p></fn><fn id="t3-fn2"><label>a</label><p>This category includes any unknown or not applicable values.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl4"><label>Table 4</label><caption><title>Overall survival by treatment arm in pre-defined patient subgroups</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="char" char=""/><col align="center"/><col align="char" char=""/><col align="char" char=""/><col align="char" char=""/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="2" align="center" valign="top" charoff="50"><italic><bold>N</bold></italic><hr/></th><th colspan="4" align="center" valign="top" charoff="50"><bold>Univariate cox regression model</bold><hr/></th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50"><bold>CD</bold></th><th align="center" valign="top" charoff="50"><bold>CP</bold></th><th align="center" valign="top" charoff="50"><bold>HR</bold></th><th align="center" valign="top" charoff="50"><bold>95&#x00025; CI</bold></th><th align="center" valign="top" charoff="50"><bold>Subgroup</bold>
<italic><bold>P</bold></italic><bold>-value</bold></th><th align="center" valign="top" charoff="50"><bold>Interaction</bold>
<italic><bold>P</bold></italic><bold>-value</bold><xref ref-type="fn" rid="t4-fn2">a</xref></th></tr></thead><tbody valign="top"><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>Age, years</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003c;70</td><td align="char" valign="top" char="." charoff="50">395</td><td align="char" valign="top" char="." charoff="50">423</td><td align="char" valign="top" char="." charoff="50">0.98</td><td align="char" valign="top" char="." charoff="50">0.83, 1.16</td><td align="char" valign="top" char="." charoff="50">0.80</td><td align="char" valign="top" char="." charoff="50">0.61</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02a7e;70</td><td align="char" valign="top" char="." charoff="50">71</td><td align="char" valign="top" char="." charoff="50">86</td><td align="char" valign="top" char="." charoff="50">1.10</td><td align="char" valign="top" char="." charoff="50">0.76, 1.58</td><td align="char" valign="top" char="." charoff="50">0.62</td><td align="char" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>BMI, kg&#x02009;m</italic><sup>&#x02212;<italic>2</italic></sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003c;30</td><td align="char" valign="top" char="." charoff="50">378</td><td align="char" valign="top" char="." charoff="50">399</td><td align="char" valign="top" char="." charoff="50">1.00</td><td align="char" valign="top" char="." charoff="50">0.85, 1.19</td><td align="char" valign="top" char="." charoff="50">0.98</td><td align="char" valign="top" char="." charoff="50">0.74</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02a7e;30</td><td align="char" valign="top" char="." charoff="50">88</td><td align="char" valign="top" char="." charoff="50">110</td><td align="char" valign="top" char="." charoff="50">0.95</td><td align="char" valign="top" char="." charoff="50">0.67, 1.35</td><td align="char" valign="top" char="." charoff="50">0.76</td><td align="char" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>TFI, months</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;6&#x02013;12</td><td align="char" valign="top" char="." charoff="50">161</td><td align="char" valign="top" char="." charoff="50">183</td><td align="char" valign="top" char="." charoff="50">1.01</td><td align="char" valign="top" char="." charoff="50">0.80, 1.28</td><td align="char" valign="top" char="." charoff="50">0.92</td><td align="char" valign="top" char="." charoff="50">0.86</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02a7e;12</td><td align="char" valign="top" char="." charoff="50">305</td><td align="char" valign="top" char="." charoff="50">326</td><td align="char" valign="top" char="." charoff="50">0.99</td><td align="char" valign="top" char="." charoff="50">0.81, 1.21</td><td align="char" valign="top" char="." charoff="50">0.90</td><td align="char" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>Measurable disease</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;No</td><td align="char" valign="top" char="." charoff="50">137</td><td align="char" valign="top" char="." charoff="50">138</td><td align="char" valign="top" char="." charoff="50">0.88</td><td align="char" valign="top" char="." charoff="50">0.65, 1.21</td><td align="char" valign="top" char="." charoff="50">0.56</td><td align="char" valign="top" char="." charoff="50">0.31</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Yes</td><td align="char" valign="top" char="." charoff="50">329</td><td align="char" valign="top" char="." charoff="50">371</td><td align="char" valign="top" char="." charoff="50">1.07</td><td align="char" valign="top" char="." charoff="50">0.90, 1.27</td><td align="char" valign="top" char="." charoff="50">0.47</td><td align="char" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>Number of prior lines</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="char" valign="top" char="." charoff="50">408</td><td align="char" valign="top" char="." charoff="50">418</td><td align="char" valign="top" char="." charoff="50">0.99</td><td align="char" valign="top" char="." charoff="50">0.84, 1.17</td><td align="char" valign="top" char="." charoff="50">0.92</td><td align="char" valign="top" char="." charoff="50">0.98</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02a7e;2</td><td align="char" valign="top" char="." charoff="50">58</td><td align="char" valign="top" char="." charoff="50">88</td><td align="char" valign="top" char="." charoff="50">0.97</td><td align="char" valign="top" char="." charoff="50">0.65, 1.46</td><td align="char" valign="top" char="." charoff="50">0.74</td><td align="char" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="7" align="left" valign="top" charoff="50"><italic>ECOG PS</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;0</td><td align="char" valign="top" char="." charoff="50">295</td><td align="char" valign="top" char="." charoff="50">329</td><td align="char" valign="top" char="." charoff="50">0.99</td><td align="char" valign="top" char="." charoff="50">0.81, 1.20</td><td align="char" valign="top" char="." charoff="50">0.92</td><td align="char" valign="top" char="." charoff="50">0.95</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02a7e;1</td><td align="char" valign="top" char="." charoff="50">171</td><td align="char" valign="top" char="." charoff="50">180</td><td align="char" valign="top" char="." charoff="50">0.99</td><td align="char" valign="top" char="." charoff="50">0.78, 1.27</td><td align="char" valign="top" char="." charoff="50">0.95</td><td align="char" valign="top" charoff="50">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="t4-fn1"><p>Abbreviations: BMI=body mass index; CD=carboplatin-pegylated liposomal doxorubicin; CI=confidence interval; CP=carboplatin-paclitaxel; ECOG PS=Eastern Cooperative Oncology Group performance status; HR=hazard ratio; TFI=treatment-free interval.</p></fn><fn id="t4-fn2"><label>a</label><p>Interaction test is the <italic>P</italic>-value associated with the interaction term in the Cox regression model containing treatment effect, subgroup variable, and their interaction.</p></fn></table-wrap-foot></table-wrap></floats-group></article>